Viatris Inc. (Nasdaq: VTRS) announced on July 29 that the FDA has approved Gwyn Lo (norelgestromin and ethinyl estradiol transdermal system), a new once-weekly contraceptive patch delivering a lower dose of estrogen than some existing patch options. The approval covers women with a body mass index below 30 kg/m squared who are appropriate candidates for a combined hormonal contraceptive. Viatris expects the patch to become commercially available later this year, though it has not disclosed pricing.

The Regulatory Pathway

The FDA cleared Gwyn Lo under the 505(b)(2) regulatory pathway, a route that lets a company rely in part on the FDA’s previous findings about a related, already-approved drug rather than generating every piece of safety and efficacy data entirely from scratch. In this case, that means the pathway builds on the agency’s existing body of knowledge about transdermal hormonal contraceptives generally, while Viatris still had to run its own trial program to support Gwyn Lo’s specific formulation and lower estrogen dose.

What the Phase 3 Trial Showed

That trial program centered on the Phase 3 Luminous Study (NCT05139121). Its primary endpoint was the Pearl Index, a standard measure in contraceptive research defined as the number of pregnancies per 100 woman-years of use; in the efficacy-evaluable population of women ages 18 to 35, Gwyn Lo’s Pearl Index came in at 4.14, with a 95% confidence interval of 2.77 to 5.95. The study also tracked how well the patch stayed on: of the 39,790 individual patches applied over the year-long trial, only 1.3% fully detached, which Viatris and outside coverage of the data have both described as strong real-world adhesion. Cycle control, meaning how predictable a woman’s bleeding pattern is on the drug, also improved over time in the study, with unscheduled bleeding or spotting affecting 34.5% of cycles in the first cycle and dropping to 20.0% by the thirteenth cycle.

Safety Profile

On safety, the most common adverse reactions reported in 2% or more of participants were application site irritation (4.8%), application site erythema (3.7%), application site itching (3.7%), intercycle bleeding (3.9%), heavy withdrawal bleeding (2.0%), and nausea (2.0%). Separately, Gwyn Lo carries the same class-wide contraindications common to combined hormonal contraceptives: it should not be used by women who smoke and are over 35, due to increased cardiovascular risk, and it is contraindicated outright in women with a BMI of 30 kg/m squared or higher, a group the data suggest may also face a greater risk of blood clots on this therapy than women with a lower BMI. Viatris Chief R&D Officer Philippe Martin highlighted that the approved label specifically includes efficacy data for women with a BMI of 25 to just under 30, a subgroup the company says carries no BMI-based restriction on use within that approved range; that is a characterization of the label’s scope from Viatris, not an independent clinical assessment.

Real-World Wear Testing

Viatris also cited four separate Phase 1 studies testing whether the patch keeps delivering its dose consistently under everyday conditions that might loosen adhesive, including a sauna, a whirlpool, treadmill exercise, and a cold-water bath; the company reported consistent drug delivery across those conditions, though it did not release the underlying numerical adhesion or absorption data from those specific studies in this release.

How It Compares to Existing Patches

Gwyn Lo’s estrogen dose sets it apart from the older transdermal contraceptive patches already on the market. Existing weekly patches sold as Xulane and its generic equivalents deliver 150 micrograms of norelgestromin and 35 micrograms of ethinyl estradiol per day, according to their FDA labeling. Gwyn Lo delivers a higher dose of norelgestromin, at 220 micrograms per day, but a lower dose of ethinyl estradiol, at 20 micrograms per day, roughly 43% less estrogen daily than the older patches. Since estrogen dose is a key factor in a combined hormonal contraceptive’s cardiovascular risk profile, a lower-estrogen patch option, if it holds up in broader use, could matter to prescribers weighing that tradeoff for individual patients, though the Luminous Study data summarized above is the only clinical evidence available on Gwyn Lo specifically so far.

The Broader Contraceptive Landscape

Viatris frames the launch against a broader unmet need in contraceptive care rather than positioning Gwyn Lo as solving a single narrow problem. The company cites a National Center for Health Statistics estimate that 41.6% of U.S. pregnancies in 2019 were unintended, and a 2023 CDC survey finding that 18.1% of women who had used a contraceptive method in the prior year had switched or stopped it, with 42.8% of that group saying they simply did not like the method they had been using. Those figures come from the cited federal health agencies rather than being generated by Viatris itself, and they describe the broader contraceptive landscape rather than any outcome specific to Gwyn Lo.

What’s Next

Gwyn Lo is a trademark of Mylan Pharmaceuticals Inc., a Viatris company, and builds on Viatris’s existing transdermal drug-delivery portfolio in women’s health. Viatris says it will share additional commercial details, including timing and pricing, during an upcoming financial results call rather than in this approval announcement. This article covers a regulatory approval and underlying trial data already published by the company; it is for informational purposes only, does not constitute investment advice, and is not medical advice.

Sources

• Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch, PRNewswire, July 29, 2026.
• XULANE – norelgestromin and ethinyl estradiol patch, labeling, cited for comparative dosing information on existing transdermal contraceptive patches.

Editorial Disclosure

This article is based on a press release issued by Viatris Inc. on July 29, 2026, distributed via PRNewswire, with comparative dosing information drawn from FDA-approved labeling for Xulane, cited above. Viatris trades on the Nasdaq under the ticker VTRS. BioTech Stocks Daily was not compensated for this coverage. Statements regarding the benefits, market availability, or commercial plans for Gwyn Lo are forward-looking and involve risks and uncertainties; pricing and launch timing have not been finalized. This article is for informational and educational purposes only, does not constitute investment advice, and is not medical advice. Consult a qualified healthcare professional for medical guidance. See our full DISCLAIMER.